Despite the rise of biologics, corticosteroids remain a vital and cost-effective first-line treatment in the CIDP market, particularly in regions with limited access to expensive immunoglobulins. Medications like prednisone are widely used to reduce inflammation and alter the immune response, offering a high initial success rate for many newly diagnosed patients. For more data on drug-based market segmentation, refer to the CIDP Market analysis.

People also ask: Are steroids used for CIDP? What are the side effects of long-term steroid use in CIDP? While effective for short-term induction, the long-term use of steroids is often limited by side effects such as weight gain, osteoporosis, and diabetes, leading many patients to eventually transition to maintenance therapies.

The market for corticosteroids is expected to remain stable due to their affordability and established clinical protocols. They serve as a crucial bridge therapy, allowing patients to achieve remission while long-term, more specialized treatment plans are developed by their neurology teams.